All In Biotech

Drug Trial Radar · NCT04502394

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Aug 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Feb 23, 2021

Primary completion

Oct 2022

Study completion Mar 2024

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

Conditions

  • Diffuse Large B Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma

Interventions

  • KRT-232Drug

    KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth

  • acalabrutinibDrug

    acalabrutinib is a BTK inhibitor anticancer drug taken by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Objective Phase 1b:To determine the KRT-232 maximum tolerated dose/ maximum administered dose (MTD/MAD) and recommended Phase 2 Dose (RP2D) in combination with acalabrutinib in subjects with R/R DLBCL or R/R CLLTime frame: 56 Days
  2. Primary Objective Phase 2: Cohort 1: To determine the complete response (CR)Time frame: 1 Year
  3. Primary Objective Phase 2: Cohort 2: To determine the rate of CR/complete remission with incomplete hematologic recovery (CRi) rate in R/R CLLTime frame: 1 Year

Locations

45 sites in 11 countries. Site status is shown where the registry gives one.

  • Goshen Center for Cancer Care

    Goshen, Indiana · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Royal Adelaide Hospital

    Adelaide, Australia · Recruiting

  • Eastern Health - Box Hill Hospital

    Box Hill, Australia · Recruiting

  • Barwon Health

    Geelong, Australia · Recruiting

  • Royal Perth Hospital

    Perth, Australia · Recruiting

  • Antwerp University Hospital (UZA)

    Edegem, Belgium · Recruiting

  • Jessa Ziekenhuis

    Hasselt, Belgium · Recruiting

  • University Hospital (UZ) Leuven

    Leuven, Belgium · Recruiting

  • Fakultni Nemocnice Hradec Kralove

    Nový Hradec Králové, Czechia · Recruiting

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia · Recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia · Recruiting

  • CHU de Nantes - Hôtel-Dieu

    Nantes, France · Recruiting

  • Centre Henri Becquerel

    Rouen, France · Recruiting

  • CHRU de Tours - Hôpital Bretonneau

    Tours, France · Recruiting

  • Centro Riferimento Oncologico - Aviano

    Aviano, Italy · Recruiting

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy · Recruiting

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy · Recruiting

  • Centro Ricerche Cliniche di Verona s.r.l.

    Verona, Italy · Recruiting

  • Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii

    Gdansk, Poland · Recruiting

  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii

    Gdansk, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach - Klinika Transplantacji Szpiku i Onkohematologii

    Gliwice, Poland · Recruiting

  • Pratia MCM Krakow

    Krakow, Poland · Recruiting

  • Szpital Uniwersytecki Krakow - Oddzial Kliniczny Hematologii

    Krakow, Poland · Recruiting

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu

    Wroclaw, Poland · Recruiting

  • Hospital de Braga

    Braga, Portugal · Recruiting

  • Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria

    Lisbon, Portugal · Recruiting

  • Champalimaud Cancer Center

    Lisbon, Portugal · Recruiting

  • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE

    Porto, Portugal · Recruiting

  • Centro Hospitalar de Vila Nova de Gaia/Espinho EPE

    Vila Nova de Gaia, Portugal · Recruiting

  • National Cancer Center

    Goyang, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.